Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013.

[1]  M. Tschan,et al.  Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma , 2019, Cells.

[2]  V. Arndt,et al.  Evaluation of completeness of case ascertainment in Swiss cancer registration , 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[3]  Lars Bullinger,et al.  Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. Arndt,et al.  Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. , 2017, Cancer epidemiology.

[5]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[6]  R. Bouabdallah,et al.  Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies , 2016, Oncotarget.

[7]  E. Roman,et al.  Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15 , 2016, Cancer epidemiology.

[8]  M. Bottai,et al.  The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study , 2015, BMC Cancer.

[9]  R. Greil,et al.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.

[10]  C. Clarke,et al.  Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis , 2015, Cancer.

[11]  C. Reyes,et al.  Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States , 2015, Annals of Hematology.

[12]  M. Sáez,et al.  Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain , 2013, Haematologica.

[13]  C. Stiller,et al.  Incidence, survival and prevalence of myeloid malignancies in Europe. , 2012, European journal of cancer.

[14]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Juliusson,et al.  Acute myeloid leukemia in the real world: why population-based registries are needed. , 2012, Blood.

[16]  K. Döhner,et al.  The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. , 2011, Blood.

[17]  D. Covas,et al.  Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil , 2010, Medical oncology.

[18]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[19]  Lucy Skrabanek,et al.  MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. , 2009, Blood.

[20]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[21]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[22]  Ram C Tiwari,et al.  Efficient interval estimation for age-adjusted cancer rates , 2006, Statistical methods in medical research.

[23]  M. Lübbert,et al.  Acute Myeloid Leukemia: Epidemiology and Etiology , 2006, Cancer.

[24]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[25]  E. Feuer,et al.  Confidence intervals for directly standardized rates: a method based on the gamma distribution. , 1997, Statistics in medicine.

[26]  C. Brown.  The statistical comparison of relative survival rates. , 1983, Biometrics.

[27]  P. Sonneveld,et al.  Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012 , 2016, Leukemia.

[28]  A. Polednak.  Recent improvement in completeness of incidence data on acute myeloid leukemia in US cancer registries. , 2014, Journal of registry management.

[29]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[30]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.